Short answer
Denali Therapeutics Inc. (DNLI) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $18M with net income of $70M.
Q3 2026 key financials · XBRL
- Revenue
- $18M
- +393.3% QoQ
- Net income
- $70M
- +155.3% YoY · +155.0% QoQ
- Operating margin
- -713.0%
- EPS (diluted)
- $0.38
- +151.4% YoY · +155.9% QoQ
Source: XBRL data from the Denali Therapeutics Inc. (DNLI) Q3 2026 10-Q on SEC EDGAR. USD.
Denali Therapeutics Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $17.8M, versus $0 prior year, from AVLAYAH commercialization
- Operating loss $126.8M, operating margin -713.1% versus not meaningful prior year
- Net income $70.1M versus $126.9M loss, including $194.0M priority review voucher gain
- Cash, equivalents and marketable securities $1.0B; operating cash use $345.6M year-to-date
- AVLAYAH revenue not expected to offset expenses near term; zafinofusp BLA submission remains on track for 2027
Risk Factors
- No material changes to risk factors previously disclosed in the 2025 Form 10-K and 2026 quarterly filings
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Denali Therapeutics Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.